Global Cancer Biomarker Testing Market - 2025-2033

The global cancer biomarker testing market reached US$24.86 billion in 2024 and is expected to reach US$67.74 billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.

Cancer biomarker testing analyzes biological markers that indicate the presence or progression of cancer. These biomarkers can include proteins, genes, or other substances produced by cancer cells or by the body in response to cancer. The primary applications of cancer biomarker testing are early detection, diagnosis, prognosis prediction, and assessing how well treatments are working.

Identifying specific biomarkers in a patient's cancer enables more personalized treatment plans, ensuring that the most effective therapies are selected. Biomarker testing is crucial for enhancing diagnosis accuracy, guiding treatment choices, and monitoring for any signs of cancer recurrence.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cancer

The rising incidence of cancer is expected to significantly drive the growth of the cancer biomarker testing market as healthcare systems focus on improving early detection, personalized treatment, and ongoing monitoring. With an increasing number of cancer cases worldwide, there is a huge demand for precise diagnostic tools that can identify cancer at earlier, more treatable stages, enabling better patient outcomes. For instance, according to the International Agency for Research on Cancer, in 2022 there were 1.46 million new lung cancer cases diagnosed. The number of new prostate cancer cases is expected to reach 3.13 million in 2025. With the growing number of cancer cases, the demand for different biomarkers is expected to grow.

Biomarker testing allows for targeted therapies, reducing trial-and-error treatment methods and minimizing side effects, which is particularly important as cancer treatments become more complex. Additionally, the growing emphasis on precision medicine, along with advancements in genomic research, is making biomarker testing more accessible and effective. As the global cancer burden rises, healthcare providers and researchers are increasingly adopting biomarker testing to tailor treatments and improve patient care, fueling market expansion.

High Costs of Biomarker Tests

The high costs of cancer biomarker tests present a significant challenge to the widespread adoption of these technologies, particularly in resource-limited settings. These tests often rely on cutting-edge technologies and specialized expertise, driving up their price. For healthcare systems already struggling with budget constraints, integrating biomarker testing into routine care becomes a difficult financial decision. This economic barrier not only limits the availability of early detection and personalized treatment but also underscores the need for more affordable solutions to ensure equitable access to cancer care globally.

Segment Analysis

The global cancer biomarker testing market is segmented based on the test type, product type, cancer type, application, and region.

Next-generation sequencing (NGS) platforms are expected to dominate the cancer biomarker testing market.

Next-generation sequencing (NGS) refers to advanced sequencing technologies that allow for high-throughput, rapid, and cost-effective analysis of entire genomes or targeted regions of interest. In cancer biomarker testing, NGS has become a critical tool due to its ability to provide deep insights into the genetic makeup of tumors, enabling more precise detection, diagnosis, and treatment strategies.

Next-generation sequencing (NGS) platforms are poised to dominate the cancer biomarker testing market due to their unparalleled ability to provide comprehensive and high-throughput genomic insights. Several advanced next-generation sequencing tests and platforms are being introduced and research is advancing in improving these solutions to detect the cancers. For instance, in October 2024, NeoGenomics, Inc. launched its AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).

This capability significantly enhances early cancer detection, prognosis prediction, and monitoring of treatment responses. As the demand for precision medicine grows, NGS platforms are increasingly favored for their accuracy, scalability, and versatility, positioning them in a significant position in the market share.

Geographical Analysis

North America is expected to dominate the cancer biomarker testing market

North America holds a dominant position in the cancer biomarker testing market, driven by its sophisticated healthcare infrastructure and substantial investments in research and development. The region's access to cutting-edge technologies, including Next-Generation Sequencing (NGS) and liquid biopsy, accelerates the integration of advanced cancer biomarker testing into clinical practice.

The region's growth in the market is further enhanced by the presence of leading biotechnology and pharmaceutical companies, which are at the forefront of innovating and commercializing new biomarker tests, propelling market growth.

Moreover, North America's strong emphasis on precision medicine and personalized treatment further boosts demand for cancer biomarker testing, as it plays a crucial role in tailoring therapies to individual patients. The rising cancer incidence, coupled with an increasing focus on early detection and public awareness, has created a significant need for reliable diagnostic tools.

Competitive Landscape

The global market players in the cancer biomarker testing market are F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Guardant Health, Agilent Technologies, Inc., Quanterix, Exact Sciences Corporation, QIAGEN and Takara Bio Inc., among others.

Key Developments

• In August 2024, Illumina, Inc. received Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications.
• In April 2024, Takara Bio USA, Inc. launched its Shasta Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer biomarker testing market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.